logo
What's To Lose? How Mounjaro Has Taken Over As The Cult Weight Loss Drug In The UAE

What's To Lose? How Mounjaro Has Taken Over As The Cult Weight Loss Drug In The UAE

First there was botox, now there's Mounjaro. Gaining popularity at warp speed, the potion that promises to banish food noise from your brain is swiftly needling its way through the UAE – but at what cost?
'Looks like Ozempic face to me.' 'No one loses that much weight just from hiking.' Choose any celebrity who has recently undergone a dramatic 'body transformation', and their – alleged! – usage of weight loss injections haunts social media accounts. A quick scroll of the comments on every major red carpet sees armchair juries rechristening events as the 'Ozempic Games', a nod to increasingly thinner bodies at premieres, galas, and photo calls.
'Everyone I know is on it,' says Noor, a Dubai-based PR specialist, adding, 'It's become beyond casual to take as needed; we all micro-dose it. It's become totally accepted. It's hard to believe that anyone who has suddenly lost weight, even gradually, has done so naturally anymore, when every other person you know is now on Mounjaro.'
Dr Aws Khidir Jassim, a general consultant and bariatric surgeon at Dubai's Gargash Hospital says he sees roughly 15 patients daily seeking advice for weight loss either by medications or weight-reduction surgeries. 'These medications have revolutionised weight reduction management,' he says. He describes them as a means of prevention, reducing the risk of more extreme intervention in the future. 'Obese patients with certain BMI criteria are eligible to take GLP-1s, otherwise they will keep putting on weight to the point that medications will be of no use and surgery will be needed,' he adds.
Originally developed to manage diabetes, the weekly, self-administrated shots are increasingly used off – label for weight loss – catapulted into the mainstream as the newest must-have to achieve one's ideal appearance. Known collectively as GLP-1s, and utilising the active ingredients semaglutide and tizepatide, products like Ozempic, Mounjaro, and Wegovy work by stimulating the body's insulin release, which reduces glucose levels and suppresses the hormones that cause feelings of hunger. The actual weight loss is the natural effect of eating less.
According to analysis group Trilliant Health, one-third of GLP-1s prescriptions worldwide are now for off -label usage. Aesthetics authority Dana Omari welcomes discussions about body modifications, tracking trends including GLP-1s usage on her Instagram account @igfamousbydana. The Palestinian commentator agrees that the medication should be seen as a helpful tool for weight loss, rather than a shortcut. 'These medications are amazing because they help address biochemical issues like cravings,' she notes. 'For people to say it's cheating means they believe your figure must be earned, which is wild to me. If I'm fit, it doesn't take away from other people being fit. I don't believe a body must be earned because that implies that socially undesirable bodies are punishment, and that we're in competition with each other.'
Dr Jassim is also sceptical of the blanket criticism. 'The concept that these medications are cheating tools is far from reality,' he explains. 'It is just like telling someone [with a] severe bacterial infection, don't take antibiotics and your immunity will take care of your infection and resolve it.'
Dana maintains that GLP-1s' ability to change lives means they will be much more than a passing trend. 'We are seeing people smoke less, drink less, binge eat less, bite their nails less, have better cholesterol, better blood sugar, lower incidence of heart disease, improved fertility, fewer PCOS symptoms… This is a medication that will stick around beyond weight loss.' On the fertility front, Noor adds, 'Many of my friends in their late 30s struggling with IVF have been prescribed it to boost their fertility as well as lower their weight gained by the steroids and medication taken during the process. It's been very helpful for them.'
Of course, the jabs aren't without risks, with potential side effects including decreased kidney and pancreas function, hair loss, lupus, poor eyesight, and other symptoms commonly related to low nutritional intake. Dr Jassim advises that women consult with a doctor before starting an appetite suppressant, who can advise them on the best brand for their needs, when to update their dosage, and then once at their goal weight, how to taper off their treatment for maintenance.
But with several brands available without prescription and over the counter in some Gulf states, it's estimated that the majority of regional users are not under the supervision of a doctor. Sara*, a creative professional in her early 30s who lives outside the UAE says she considers the injections to be an addition to her beauty and wellness routine, like Botox or collagen supplements. She stocks up on her syringes when visiting Dubai for work. 'It's more expensive, but much easier to buy in Dubai,' she explains, 'so it depends on how much you're willing to spend for the convenience.' While she knows self-administrating may have risks, she's confident in her ability to judge when to go up to the next dosage level. 'So many of my friends [in the UAE] use Mounjaro. We are all very open about it. It's hard to hide it when we go out and end up with five of us sharing two starters for dinner!'
Like Sara, Noor confirms that administering this weekly injection is just another part of a contemporary health regime, like taking a Pilates class or a vitamin. 'Most of my friends, both men and women, take it as extra support in addition to an exercise routine and dieting, helping to alleviate hunger and cravings.'
Social media has played a significant part in the popularity of GLP-1s. Sara points to a corner of TikTok known as 'SkinnyTok' in being instrumental to teaching her the ways of the jab. On this side of the algorithm, you can scroll through videos of influencers sharing their 'what I eat in a day on Ozempic' food diaries, time-delay montages of women jabbing themselves in their ever-shrinking stomachs, and tutorials on how to hack the pre-filled pens in order to suck out every last drop of appetite-inhibiting elixir. The vibe swings between cheery and bright, and an almost solemn reverence to the act of getting thin.
There's a touch of '90s diet culture around it, with pictures of Calvin Klein-era Kate Moss and other waify icons serving as style inspo for once the viewer loses those hip dips. While positioned as a dream drug for those with higher BMIs, SkinnyTok also showcases women who appear to be using the drugs to go from a medium or slim build to extra thin; a concerning development for mental health advocates.
Dana acknowledges that SkinnyTok videos are damaging as they promote thinness as aspirational. 'But let's be honest. That [ideal] never left the building. At the end of the day, I think honest and factual information [for] education is better than misinformation or no information.' As for the celebrities who suddenly dropped a third of their body weight from 'running after their kids' or by 'switching to coconut oil', Dana says that fans will respect those who are upfront about their routines. 'My take is to be honest, or be quiet. It's better if you're open about it because you're more relatable and destigmatising something that helped transform your life.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Department of Municipalities and Transport highlights the role of AI and digitalisation in workplace safety
Department of Municipalities and Transport highlights the role of AI and digitalisation in workplace safety

Zawya

time31 minutes ago

  • Zawya

Department of Municipalities and Transport highlights the role of AI and digitalisation in workplace safety

Abu Dhabi, UAE: The Department of Municipalities and Transport (DMT) is set to host the Occupational Health and Safety Week 2025 from 23 to 27 June. The event will feature a two-day forum exploring the theme Growth in Artificial Intelligence and Digitalisation: A Leap in the Right Direction for Workplace Safety and Health. The two-day forum highlights the Department's commitment to leveraging digital technologies and artificial intelligence to create safe and sustainable work environments. By incorporating advanced tools such as big-data analytics, the Internet of Things (IoT), and augmented and virtual reality, the forum aims to enhance performance efficiency, reduce workplace accidents and injuries, and improve risk prediction and management. Through panel discussions and specialised workshops, the event demonstrates DMT's commitment to building expertise, sharing knowledge, and enhancing partnerships at both local and international levels. These initiatives are aligned with the National Strategy for Occupational Health and Safety, and Abu Dhabi's Occupational Health and Safety System, all designed to minimise risks, improve workplace conditions, and support employee well-being. The dynamic forum will bring together leading local and international experts and provide attendees with opportunities to discover the best global and regional practices from organisations such as the International Institute of Risk Management, the Abu Dhabi Civil Defence Authority, Khalifa University, and the Integrated Transport Centre (Abu Dhabi Mobility). Panel discussions and contributions from entities such as Abu Dhabi City Municipality, Al Ain City Municipality, and Abu Dhabi Ports will focus on initiatives aimed at optimising workplace standards and promoting employee health and satisfaction. Emphasising the forum's strategic importance, HE Dr Salem Al Kaabi, Director General of Operations Affairs at DMT, said: "The second edition of the Occupational Health and Safety Week underscores our ongoing efforts to creating safer, healthier workplaces by leveraging digitalisation and artificial intelligence as transformative tools to enhance safety standards and improve employee well-being." The event will conclude with a discussion session to review key learnings and deliver recommendations to advance Abu Dhabi's occupational health and safety systems. These efforts aim to strengthen institutional integration while supporting the Emirate's vision for sustainable development and digitally adaptive communities, fostering safer and more resilient workplaces, in line with global best practices. As part of this year's activities, the Department and its affiliates will conduct various awareness campaigns aimed at elevating workplace wellbeing and safety standards across the Emirate.

DoH – Abu Dhabi and Sanofi forge strategic alliance to accelerate the development of new global vaccines in Abu Dhabi
DoH – Abu Dhabi and Sanofi forge strategic alliance to accelerate the development of new global vaccines in Abu Dhabi

Zawya

time2 hours ago

  • Zawya

DoH – Abu Dhabi and Sanofi forge strategic alliance to accelerate the development of new global vaccines in Abu Dhabi

Abu Dhabi, United Arab Emirates: The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, has signed a Memorandum of Understanding (MoU) with Sanofi, a research and development-driven, AI-powered healthcare biopharma company at the BIO International Convention 2025, in Boston, USA. The collaboration will leverage the Emirate's health-tech ecosystem and advanced research infrastructure to drive the development of new global vaccines and strengthen regional capabilities in vaccine manufacturing. In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi and Laurie Gery. Global Head of Business Development, Vaccines at Sanofi, the agreement was signed during the BIO International Convention in Boston, USA, by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH and Baptiste de Clarens, General Manager Greater Gulf, Vaccines at Sanofi. Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH, said: 'DoH is partnering with Sanofi to expedite the development of new global vaccines. This initiative aims to shorten the timeline from early research to public availability by utilising advanced technologies, real-time data analysis, and conducting parallel clinical trial phases. By combining Sanofi's global scientific expertise with Abu Dhabi's state-of-the-art infrastructure, we set new benchmarks for resilience, innovation and international partnerships. Abu Dhabi offers a globally connected, purpose-driven environment for leading research and together we will drive a transformative change that will safeguard the health and well-being of our community while contributing to global health security.' Both entities will work together to streamline regulatory processes, enhance manufacturing preparedness, and promote knowledge sharing between local and international experts. This partnership reflects Abu Dhabi's strategic goal to establish itself as a leading center for bio- and pharmaceutical innovation and underscores the emirate's commitment to advancing proactive, technology-driven healthcare solutions. Baptiste de Clarens, General Manager Greater Gulf, Vaccines, Sanofi, said: 'The Memorandum of Understanding signed with the Department of Health – Abu Dhabi marks an encouraging step towards advancing global health security while reflecting our shared interest in addressing global health challenges through scientific partnership. This agreement allows us to examine how Sanofi's experience in vaccine development could complement Abu Dhabi's growing R&D ecosystem. Through this initial framework, we look forward to exploring opportunities for public-private collaboration in healthcare innovation.' In addition, both the Department and Sanofi will advance clinical research and development planning, optimise resource allocation and establish the foundational terms for funding and access. These efforts are designed to enhance healthcare resilience and sustainability across Abu Dhabi's healthcare sector and beyond, expanding access to quality care for patients locally and globally. Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 15 to 21, delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Cargo, New York University Abu Dhabi (NYUAD), Khalifa University, startAD and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI). About the Department of Health – Abu Dhabi (DoH): The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual. For further information on DOH, visit and follow on X, Instagram, Facebook, LinkedIn and YouTube. For media inquiries, please contact: Mariam Al Marzooqi, msalmarzooqi@

Mayo Clinic researchers identify new immunotherapy target for ovarian cancer
Mayo Clinic researchers identify new immunotherapy target for ovarian cancer

Zawya

time3 hours ago

  • Zawya

Mayo Clinic researchers identify new immunotherapy target for ovarian cancer

Dubai, United Arab Emirates — Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, may be key in helping the immune system fight tumors in ovarian cancer. The study, published in Science Advances, could improve treatment approaches for this type of cancer. Because ovarian cancer has limited symptoms, it can go undetected until it has spread. At a later stage, it becomes challenging to treat and has had limited success from existing immunotherapies and checkpoint inhibitors. Cryptic antigens are part of a protein — known as epitopes — that are usually hidden or inaccessible to the immune system and may be present in tumor cells. By targeting these antigens, the immune system can be effectively mobilized to attack the cancer. "These findings underscore the need to look at alternate sources of target antigens for ovarian cancer," says Marion R. Curtis, Ph.D., senior author of the study and immunologist at Mayo Clinic Comprehensive Cancer Center. "Discovering tumor-associated antigens that T cells recognize is crucial for the success of immunotherapeutic approaches in ovarian cancer, where the growth of cells that form in the ovaries multiply quickly and can invade and destroy healthy body tissue." T cells are a critical component of the adaptive immune system. Their ability to recognize and respond to specific targets is fundamental to their function. They play a significant role in developing and treating cancer and are vital in the immune system's fight against infections. In this study, the researchers characterized tumor antigens generated from ovarian cancer using multi-omics approaches to determine their ability to trigger an immune response. Multi-omics encompasses using multiple 'omes' (i.e., genome, proteome, microbiome, epigenome) to better understand the mechanisms of disease processes, detection, potential prevention and more focused therapies. Researchers have previously focused on discovering newly formed antigens (neoantigens). However, a previous study revealed that neoantigens are rarely found in ovarian cancer samples, making them unattractive targets. The next steps involve preclinical testing and clinical trials to evaluate the safety and efficacy of new immunotherapies and vaccines that target these cryptic antigens. The researchers also plan larger-scale studies to determine the prevalence of cryptic antigen expression across various tumor types, potentially paving the way for broader applications of this immunotherapy approach. Review the study for a complete list of authors, disclosures and funding.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store